Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Evan Y. Yu"'
Autor:
Laura S. Graham, George R. Schade, Petros Grivas, Jonathan L. Wright, Daniel W. Lin, Wen-Min Hou, Lawrence D. True, Peter S. Nelson, Todd Yezefski, Katie Nega, Nima Sharifi, Michael T. Schweizer, Nicholas P. Reder, Evan Y. Yu, Roman Gulati, Alvin A Matsumoto, Bruce Montgomery, Brett T. Marck, Katerina Alexander, William J. Ellis, Elahe A. Mostaghel
Publikováno v:
Prostate
Background Localized prostate cancers (PCs) may resist neoadjuvant androgen receptor (AR)-targeted therapies as a result of persistent intraprostatic androgens arising through upregulation of steroidogenic enzymes. Therefore, we sought to evaluate cl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::329a963164137ffb64e3f658349c0b2a
https://europepmc.org/articles/PMC8044035/
https://europepmc.org/articles/PMC8044035/
Autor:
Lu Xu, Emmanuel S. Antonarakis, Evan Y. Yu, Se Hoon Park, Yi-Hsiu Huang, Jeri Kim, Mostefa Bennamoun
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Cohort A of the phase 1b/2 KEYNOTE-365 study (NCT02861573) demonstrated promising antitumor activity with pembrolizumab + olaparib in patients with mCRPC unselected for homologous recombination deficiency. The prostate-specific antigen (PS
Autor:
Ruth Etzioni, Daniel M. Lim, Serge Aleshin-Guendel, Jonathan T. Wingate, Heather H. Cheng, Roman Gulati, Agnes M. Gawne, Evan Y. Yu
Publikováno v:
The Prostate. 78:1077-1083
BACKGROUND Optimal utilization of novel therapies for advanced prostate cancer is challenging without a validated surrogate efficacy endpoint. Ongoing trials are using durable undetectable prostate-specific antigen (PSA) levels as a marker of efficac
Autor:
Steve Y. Cho, Daniel H. Shevrin, Bridget F. Koontz, Michael A. Carducci, Jonathan McConathy, Rana R. McKay, David A. Mankoff, Fenghai Duan, Evan Y. Yu, Volkan Beylergil, Glenn Liu, Neha Vapiwala, Christos Kyriakopoulos, Terence Z. Wong, Yu-Hui Chen
Publikováno v:
Journal of Clinical Oncology. 39:TPS5098-TPS5098
TPS5098 Background: Radiation therapy (RT) to the prostate bed and pelvic nodes with short-term androgen deprivation therapy (STAD) is considered a standard of care (SOC) salvage therapy (ST) paradigm for prostate cancer (PC) patients (pts) with post
Autor:
Emmanuel S. Antonarakis, Adam S. Kibel, Evan Y. Yu, Lawrence I. Karsh, Aymen Elfiky, Neal D. Shore, Nicholas J. Vogelzang, John M. Corman, Frederick E. Millard, Johnathan C. Maher, Nancy N. Chang, Todd DeVries, Nadeem A. Sheikh, Charles G. Drake
Publikováno v:
Clinical Cancer Research. 23:2451-2459
Purpose: STAND, a randomized, phase II, open-label trial (NCT01431391), assessed sequencing of sipuleucel-T (an autologous cellular immunotherapy) with androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC) patients at h
Autor:
Jonathan McConathy, Daniel H. Shevrin, Bridget F. Koontz, Neha Vapiwala, Glenn Liu, Steve Y. Cho, Volkan Beylergil, Terence Z. Wong, Fenghai Duan, Yu-Hui Chen, Christos Kyriakopoulos, Rana R. McKay, David A. Mankoff, Evan Y. Yu, Michael A. Carducci
Publikováno v:
Journal of Clinical Oncology. 39:TPS267-TPS267
TPS267 Background: Radiation therapy (RT) to the prostate bed and pelvic nodes with short-term androgen deprivation therapy (STAD) is considered a standard of care (SOC) salvage therapy (ST) paradigm for prostate cancer (PC) patients (pts) with post-
Autor:
Evan Y. Yu, Alberto Briganti, Jorge A. Ortiz, Murilo Luz, Hiroyoshi Suzuki, Rongjin Guan, Antoine Thiery-Vuillemin, Thierry Lebret, Declan G. Murphy, Andrew J. Armstrong, Christopher Michael Pieczonka
Publikováno v:
Journal of Clinical Oncology. 38:TPS5593-TPS5593
TPS5593 Background: Patients (pts) with prostate cancer treated with prolonged androgen deprivation therapy (ADT) will eventually develop castration-resistant disease. Treatment of pts with nmCRPC with darolutamide (DARO) delays the development of me
Publikováno v:
European urology focus. 5(2)
Clinical trial data forms the foundation of how we treat men with metastatic prostate cancer who are initiating therapy. However, clinical trial data does not answer everything; hence, good clinical practice, pragmatism, and occasionally extrapolatio
Autor:
James Bailen, Michael L. Hancock, Joel Bass, Michael Gambla, Robert Given, Franklin Chu, Franklin Gaylis, Marc M. Gittelman, Mitchell S. Steiner, Christopher C. Coss, Laurence Belkoff, Evan Y. Yu, Robert H. Getzenberg, Ronald F. Tutrone, Thomas E. Keane, Jordan Smith, James T. Dalton
Publikováno v:
European Urology. 67:334-341
Background A need remains for new therapeutic approaches for men with advanced prostate cancer, particularly earlier in the disease course. Objective To assess the ability of an oral selective estrogen receptor α agonist (GTx-758) to lower testoster
Autor:
Michael T. Schweizer, Evan Y. Yu
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 8 (2016)
While initially effective, androgen deprivation therapy (ADT) is not curative, and nearly all men with advanced prostate cancer will eventually progress to the more resistant, and ultimately lethal form of the disease, so called castration-resistant